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Abstract: A (core/shell)/shell nanostructure (production performance≈ 50%, mean diameter≈ 330 nm)
was built using maghemite, PLGA, and chitosan. An extensive characterization proved the complete
inclusion of the maghemite nuclei into the PLGA matrix (by nanoprecipitation solvent evaporation)
and the disposition of the chitosan shell onto the nanocomposite (by coacervation). Short-term
stability and the adequate magnetism of the nanocomposites were demonstrated by size and elec-
trokinetic determinations, and by defining the first magnetization curve and the responsiveness of
the colloid to a permanent magnet, respectively. Safety of the nanoparticles was postulated when
considering the results from blood compatibility studies, and toxicity assays against human colonic
CCD-18 fibroblasts and colon carcinoma T-84 cells. Cisplatin incorporation to the PLGA matrix
generated appropriate loading values (≈15%), and a dual pH- and heat (hyperthermia)-responsive
drug release behaviour (≈4.7-fold faster release at pH 5.0 and 45 ◦C compared to pH 7.4 and 37
◦C). The half maximal inhibitory concentration of the cisplatin-loaded nanoparticles against human
lung adenocarcinoma A-549 cells was ≈1.6-fold less than that of the free chemotherapeutic. Such a
biocompatible and tri-stimuli responsive (maghemite/PLGA)/chitosan nanostructure may found a
promising use for the effective treatment of lung cancer.
Keywords: chitosan; heat-triggered drug release; magnetic drug delivery; pH-responsive drug
release; PLGA; triple stimuli-responsive nanoparticle
1. Introduction
Control of the in-vivo fate of antitumour agents (genes and/or drugs), when they
are site-specific delivered by biodegradable and biocompatible nanoparticles (NPs), has
been reported to optimize cancer therapy outcomes in terms of efficacy and safety [1–3].
Remarkably, Nanotechnology has also contributed to the implementation of combination
therapies against this malignant disease, e.g., chemotherapy and photodynamic therapy [4],
chemotherapy and photothermal therapy [5], and chemotherapy and hyperthermia [6].
To these objectives, the introduction of passive and active drug targeting strategies in
NP engineering has resulted to be a key aspect to be seriously considered [7,8]. These wise
formulation strategics are focused on the surface functionalization of the NP structure with:
(i) hydrophilic polymer chains, classically poly(ethylene glycol) (PEG), to develop stealth
particles that can exploit the enhanced permeability and retention (EPR) effect commonly
found at the tumour site [9]; and, (ii) molecules capable of interacting with receptors at
the cancer cell membrane (ligand-mediated targeting) [10]. Also, the nanostructure can
be optimized to assure the triggered (selective) release of the chemotherapeutics in deep
contact with the malignant cells. The later are stimuli-sensitive drug delivery systems
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releasing loaded contents on demand when they suffer modifications in their properties and
architecture under specific bioenvironmental changes [11]. In this line, the development of
nanoparticulate systems exhibiting a pH-responsive drug release behaviour [12,13], or heat
(hyperthermia)-triggered drug release capacities [14,15], has been described to facilitate
a better accumulation of the chemotherapeutics at the tumour mass. Probably, a more
relevant approach to beat the challenges is the formulation of multi-stimuli responsive
nanostructures if optimized levels of the antitumour agent are intended in deep contact
with the cancer cells or even intracellularly. To that aim, nanoengineering strategies became
more complex and difficult to develop [16,17].
In this scenery, superparamagnetic iron oxides are considered to be relevant nanoma-
terials when engineering the structure of a multi-stimuli sensitive nanomedicine against
cancer [18–21]. Maghemite (γ-Fe2O3) and magnetite (Fe3O4) are the iron oxide particles
preferably introduced in the structure of magnetic nanomedicines [22]. More concretely,
including γ-Fe2O3 nuclei in the architecture of nanoparticulate system has been described
to report interesting drug delivery properties (efficient tumour targeting in response to a
magnetic field located at the cancer site) [23–25], magnetic hyperthermia characteristics to
trigger drug release and/or to generate a complementary antitumour mechanism [26,27],
and magnetic resonance imaging (MRI) contrast properties to visualize the malignant
tissue and cells [28,29].
However, the architecture of the iron oxide-based nanosystems must be improved to
assure the safety, biocompatibility, and stability of the magnetic colloid, and the vehiculiza-
tion and targeting of the therapeutic agents (drugs and/or genes). For instance, which
is possible when using polymers in the surface functionalization of these NPs: poly(D,L-
lactide-co-glycolide) (PLGA) [30], chitosan (CS) [31], or poly(ε-caprolactone) [32], to cite
just three representative examples.
PLGA nanomatrices can be advantageously used in the formulation of magnetic
nanocomposites to obtain appropriate loadings and controlled (biphasic) release profiles of
chemotherapeutics [33–35]. In addition, pH-triggered drug delivery capabilities have been
described for this biocompatible copolymer. A consequence of its improved degradation at
the acidic intratumoural pH by hydrolysis of the backbone ester linkages in its chemical
structure [36,37]. PLGA has been also used to prepare thermoresponsive nanocarriers
generating a heat-triggered release of the cargo at the targeted site [38,39]. In fact, it has
been defined an increase in the rate of polymer degradation with increasing incubation
temperatures [40], and the enhancement of the mobility of the PLGA chains at temperatures
over the glass transition temperature (Tg) of PLGA (≈40 ◦C) [39], being these key factors
activating a rapid release of the cargo. Thus, drug release from PLGA matrices could be
triggered when superparamagnetic iron oxide nuclei are embedded into them: a high
frequency alternating electromagnetic field will transform these magnetic cores into heaters
producing an increase in temperature to ≈45 ◦C [18,22,41], over the Tg of the polymer. As
a result, a fast drug release would take place at this temperature given the greater polymer
degradation and also because of the improved drug diffusion of the chemotherapeutic
molecules through the PLGA structure.
Like PLGA nanostructures, CS-based nanosystems are efficient in the tumour pH-
responsive release of drugs, given the high solubility of the polymer at these acidic pH
values [42,43]. Additionally, CS is a biocompatible and water-soluble polymer that could
be considered as an alternative to poly(ethylene glycol) (PEG) chains when engineering
long-circulating NPs. Hence, surface functionalization with CS may optimize the biodistri-
bution and therapeutic effects of PLGA-based nanomedicines by: (i) providing hydrophilic
and positively charged stealth coatings that could reduce or even inhibit protein corona
formation, thus minimizing and delaying the opsonization process to evade phagocy-
tosis [44–47], while favouring the uptake by targeted cells [48,49]; and, (ii) creating an
additional barrier to drug diffusion during the early-time burst release of the biphasic
drug release profile [50,51]. Incorporation of the CS shell onto a PLGA-based NP may
take place by an attractive interaction between the negative PLGA matrix and the positive
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polysaccharide [52], and the idea has been applied to the production of magnetopolymer
particles, i.e., (Fe3O4/PLGA)/CS [53,54] and (γ-Fe2O3/PLGA)/CS [55] nanostructures.
However, the multi-stimuli-responsive character of these (core/shell)/shell composites has
not yet been characterized.
Cisplatin, Cisplatinum, or cis-diamminedichloroplatinum(II) (CDDP) dichloride [molec-
ular weight, MW: 300.05 g/mol; water solubility: 2.53 mg/mL; n-octanol-water partition
coefficient (log POW): −2.19] has demonstrated an appropriate activity against solid tu-
mours, e.g., lung cancer, ovarian cancer, head and neck squamous cell carcinoma breast
cancer, and brain cancer [56], when administered as a single antitumour agent or in a combi-
nation chemotherapy regimen. Unfortunately, rapid biodegradation of CDDP molecules in
blood could be considered a key limitation to conventional chemotherapy (human plasma
half-life ≤ 0.5 h) [56,57]. To beat the challenge, it has been proposed the incorporation of
this chemotherapeutic into nanocarriers, e.g., PLGA- [58,59] or CS-based NPs [31,60]. That
association has reported optimized pharmacokinetics along with improved contact of the
anticancer molecules with the malignant cells. Nevertheless, greater benefits have been
associated to the engineering of stimuli-responsive nanostructures for pH-triggered [37,61]
and/or heat (hyperthermia)-triggered [41,62] drug release: CDDP release in blood is kept
to a minimum while a rapid release is then activated when the pH-responsive colloid
reaches the tumour interstitium (pH ≈ 5), and/or when this targeted site is coupled to
a high frequency alternating electromagnetic field transforming the superparamagnetic
iron oxide cores included in the nanostructure into heaters that produce heat in a con-
trolled manner (maximum temperature of ≈45 ◦C, not causing damage to healthy tissues
surrounding the tumour mass). CDDP has also been previously loaded to non-magnetic
PLGA/CS-based particles [49,63], but up to now the colloidal stability, hemocompatibility,
and suitability of these (core/shell) nanoparticulate systems for (dual) pH-triggered and
heat (hyperthermia)-triggered CDDP release was not characterized.
In this contribution, we have investigated a procedure to formulate NPs in which
γ-Fe2O3 nanocores are included into a PLGA matrix loaded with CDDP molecules and
surface functionalized by CS. Reproducible production of this (γ-Fe2O3/PLGA)/CS nanos-
tructure was demonstrated by comparing some relevant physical and chemical properties
to those of γ-Fe2O3/PLGA and CS particles. Evaluation of the toxicity of the nanocom-
posites was based on hemocompatibility studies, and tests on human colonic CCD-18
fibroblasts and human colon carcinoma T-84 cells. After defining the short-term stability of
the colloid and the in-vitro interaction with BSA, the characterization of the multi-stimuli-
responsive capabilities of these (core/shell)/shell composites started with the analysis of
their magnetic responsiveness. Then, CDDP loading to the NPs and in-vitro release was
evaluated by ultraviolet (UV) spectrophotometry. The potential use of the nanoplatform
for (dual) pH-triggered and heat (hyperthermia)-triggered CDDP release was investigated
at the acidic microenvironment typical of tumours (pH ≈ 5) and at the temperature used
in magnetic hyperthermia to trigger drug release (≈45 ◦C). To finish, cytotoxicity against
human lung adenocarcinoma A-549 cells of these CDDP-loaded magnetic nanocomposites
was evaluated. To our best knowledge, this is the first time that these (γ-Fe2O3/PLGA)/CS
(core/shell)/shell NPs have demonstrated adequate properties as magnetic-, pH- and
temperature-responsive nanostructures for the delivery of CDDP molecules to malignant
cells, and promising activity against lung cancer.
2. Materials and Methods
2.1. Materials
Deionized and filtered water was used in the experiments (Milli-Q Academic®, Milli-
pore, Molsheim, France). Resomer® RG 502 H [PLGA, 50:50 poly(D,L-lactide):poly(glycolide),
MW ≈ 7 to 17 kDa, inherent viscosity ≈ 0.16 to 0.24 dL/g), low MW CS (≈50 to 190 kDa,
determined by viscosity measurement; polydispersity not determined by the labora-
tory; 75–85% deacetylated; 99% purity level), ethylenediaminotetraacetic acid (EDTA),
monosodium citrate [NaH2(C3H5O (COO)3)], cis-diamminedichloroplatinum(II) (CDDP)
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dichloride, 3-(4,5-dimethylthiazol-2-yl)-3,5-diphenyl tetrazolium bromide (MTT) solution,
Dulbecco’s modified eagle’s medium (DMEM), phosphate buffered saline (PBS), bovine
serum albumin (BSA; heat shock fraction, ≥98% purity level), fetal bovine serum (FBS),
and Penicillin-Streptomycin solution (containing 10,000 U/mL of Penicillin and 10 mg/mL
of Streptomycin) from Merck KGaA (Gernsheim, Germany). Kolliphor® P-188 from BASF
(Ludwigshafen, Germany). Iron(III) nitrate nanohydrate [Fe(NO3)3·9H2O, MW: 404 g/mol],
iron(II) chloride tetrahydrate (FeCl2·4H2O, MW: 198.81 g/mol), potassium nitrate (KNO3),
perchloric acid (HClO4, 70%, American Chemical Society, ACS, specification, Washington,
DC, USA), hydrochloric acid (HCl, 37%, ACS specification), ethanol (EtOH, 96◦), dimethyl
sulfoxide (DMSO), and acetic acid (CH3COOH, ≥98%, ACS specification) from VWR
lnternational Eurolab S.L.U. (Barcelona, Spain). Iron trichloride hexahydrate (Cl3FeH12O6,
MW: 270.32 g/mol), polyvinyl alcohol (PVA, MW: 72,000 g/mol), HPLC-grade acetone,
citric acid (C6H8O7), ammonia (NH3, 30%, ACS specification), and sodium hydroxide
(NaOH) from Panreac Química S.L.U. (Barcelona, Spain). Disodium phosphate (Na2HPO4),
dipotassium phosphate (K2HPO4), sodium sulfate (Na2SO4), sodium chloride (NaCl),
potassium chloride (KCl), and oleic acid (≥99%, ACS specification) from Guinama S.L.U.
(Valencia, Spain). These chemicals were of analytical quality and used as received without
further purification.
2.2. Preparation of the (γ-Fe2O3/PLGA)/CS Nanostructure
The procedure followed to obtain γ-Fe2O3 NPs started with the production of Fe3O4
particles by chemical co-precipitation (Figure 1a) [64] and finalized with their oxidation
into γ-Fe2O3 (Figure 1b) [65] (n = 3). To favour the entrapment of the γ-Fe2O3 nanocores
into the PLGA matrix, their hydrophilic surface was turned into hydrophobic by using
oleic acid [53,66] (Figure 1c) (n = 3).




Figure 1. (a) Preparation of Fe3O4 NPs by chemical co-precipitation and (b) oxidation into γ-Fe2O3 particles; (c) surface 
modification of γ-Fe2O3 NPs with oleic acid; (d) formulation of CDDP-loaded γ-Fe2O3/PLGA (core/shell) particles by 
nanoprecipitation solvent evaporation; and (e) preparation of CDDP-loaded (γ-Fe2O3/PLGA)/CS (core/shell)/shell NPs by 
coacervation. 
Preparation of the γ-Fe2O3/PLGA NPs was based on the nanoprecipitation solvent 
evaporation procedure (Figure 1d) [55] (n = 3), which has been described to generate 
PLGA NPs [67]. CDDP loading to the core/shell NPs was accomplished by dissolving the 
antitumour molecule in 10 mL of the aqueous phase [PVA (1%, w/v)], at a given amount 
(up to 300 μg/mL), before incorporation of 5 mL of the acetone phase (n = 3). 
Finally, (γ-Fe2O3/PLGA)/CS nanocomposites were formulated by coacervation 
(Figure 1e) [55] (n = 3), a method habitually used to prepare CS NPs [68]. Preparation of 
CDDP-loaded (γ-Fe2O3/PLGA)/CS particles was done by using the γ-Fe2O3/PLGA NPs 
with the higher DL values (i.e., ≈16%, see Section 3.3) (n = 3). NP production performance 
(PP, %) was calculated by using Equation (1): 𝑃𝑃 % = amount of NPs obtained mgsummation of materials used in the preparation of these NPs mg × 100 (1)
2.3. Characterization 
Size and polydispersity index (PdI) of the NPs, and zeta potential (ζ) of the aqueous 
NP dispersions (≈0.1%, w/v) were characterized at room temperature and in triplicate 
(Zetasizer Nano-ZS, Malvern Instruments Ltd., Worcestershire, UK), by photon correla-
tion spectroscopy (PCS) and electrokinetic determinations, respectively. The detection 
angle was 60°. Furthermore, annular bright field scanning transmission electron micros-
copy (ABF-STEM), high-angle annular dark field scanning transmission electron mi-
croscopy (HAADF-STEM), and high-resolution transmission electron microscopy 
Figure 1. (a) Preparation of Fe3O4 NPs by chemical co-precipitation and (b) oxidation into γ-Fe2O3 particles; (c) surface
modification of γ-Fe2O3 NPs with oleic acid; (d) formulation of CD P-loaded γ-Fe2 /PLGA (core/shell) particles by
nanoprecipitation solvent evapor ti n; a d (e) pre aration of CD P-load - e2O3/PLGA)/CS (core/s )/shell NPs
by coacervation.
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Preparation of the γ-Fe2O3/PLGA NPs was based on the nanoprecipitation solvent
evaporation procedure (Figure 1d) [55] (n = 3), which has been described to generate
PLGA NPs [67]. CDDP loading to the core/shell NPs was accomplished by dissolving the
antitumour molecule in 10 mL of the aqueous phase [PVA (1%, w/v)], at a given amount
(up to 300 µg/mL), before incorporation of 5 mL of the acetone phase (n = 3).
Finally, (γ-Fe2O3/PLGA)/CS nanocomposites were formulated by coacervation
(Figure 1e) [55] (n = 3), a method habitually used to prepare CS NPs [68]. Preparation of
CDDP-loaded (γ-Fe2O3/PLGA)/CS particles was done by using the γ-Fe2O3/PLGA NPs
with the higher DL values (i.e., ≈16%, see Section 3.3) (n = 3). NP production performance
(PP, %) was calculated by using Equation (1):
PP (%) =
amount of NPs obtained (mg)
summation of materials used in the preparation of these NPs (mg)
× 100 (1)
2.3. Characterization
Size and polydispersity index (PdI) of the NPs, and zeta potential (ζ) of the aqueous NP
dispersions (≈0.1%, w/v) were characterized at room temperature and in triplicate (Zetasizer
Nano-ZS, Malvern Instruments Ltd., Worcestershire, UK), by photon correlation spectroscopy
(PCS) and electrokinetic determinations, respectively. The detection angle was 60◦. Fur-
thermore, annular bright field scanning transmission electron microscopy (ABF-STEM),
high-angle annular dark field scanning transmission electron microscopy (HAADF-STEM),
and high-resolution transmission electron microscopy (HRTEM) (Titan G2 60-300 FEI mi-
croscope, Thermo Fisher Scientific Inc., Waltham, MA, USA; accelerating voltage of 300 kV)
facilitated the visualization the particles. Drops of the colloids (≈0.1%, w/v) were poured
on formvar/carbon-coated copper microgrids and dried at room temperature. During
the TEM determinations, elemental analysis was done [energy dispersive X-ray (EDX)
spectrometer, Bruker Nano GmbH, Berlin, Germany]. Finally, short-term stability of an
aqueous dispersion of (core/shell)/shell particles (1 mg/mL, pH ≈ 6) at 25.0 ± 0.5 ◦C
was tested in triplicate. Evolution of size, PdI and ζ values of the NPs was measured as a
function of time.
Interaction of the nanocomposites with human serum proteins for possible protein
corona formation was analysed in vitro, following a previously detailed methodology
[69,70]. To that aim, 70 µL of the magnetic colloid (9.5 mg/mL) were incubated during 40 min
at 37.0 ± 0.5 ◦C in 5 mL of PBS (final concentration of 130 µg/mL of PBS) containing 0, 34 or
54 mg/mL of BSA. Size and PdI was then determined by PCS after magnetic removal of the
NPs from the media (0.4 T permanent magnet) and redispersion in water (≈0.1%, w/v).
Electrokinetic determinations were done to define qualitatively the surface disposition
of CS onto the (γ-Fe2O3/PLGA) NPs, given that the technique is most sensitive to small
modifications on the surface of iron oxide NPs [22,71]. To that objective, the evolution of the
ζ values as a function of the ionic strength (at a constant pH ≈ 6) was characterized. KNO3
was the electrolyte used to fix the ionic strengths [32,72,73], and the determinations were
done at room temperature, after 24 h of contact under stirring (200 rpm, Boeco universal
orbital shaker OS-10, Boeco, Hamburg, Germany) (n = 9). With this aim, chemical character-
ization of the (γ-Fe2O3/PLGA)/CS particles was also done by Fourier transform infrared
(FTIR) spectrometry (FT/IR-6200 spectrometer, JASCO, Easton, MD, USA; resolution of
0.25 cm−1). Significant bands of these nanocomposites were identified by comparison with
published data.
Given that the internal structure of iron oxide-based particles is considered to be a
key factor defining their magnetism [22,74], determination of the mineralogical purity and
crystallinity of the γ-Fe2O3 cores and the (core/shell)/shell particles was accomplished by
X-ray diffractometry (Philips PW1710 diffractometer, Eindhoven, The Netherlands). With
this aim, the Debye-Scherrer method was used (Cu-Kα radiation of λ = 1.5405 Å).
Magnetic properties of the (γ-Fe2O3/PLGA)/CS particles were investigated at
25.0 ± 0.5 ◦C, under the effect of a magnetic field of 0 to 4000 kA/m (Manics DSM-8
vibrating magnetometer, Toulouse, France). As well, optical visualization of the magnetic
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responsiveness of the (core/shell)/shell NPs to a 400 mT permanent magnet, placed close
to the glass vial containing the colloid (≈0.1%, w/v), was done. These are in-vitro experi-
ments widely used to evaluate the magnetic responsiveness of a nanoparticulate system,
as previously defined in the literature [22,32,75–77].
2.4. Hemocompatibility
One important aspect to consider when defining the clinical use of a nanoparticulate
system is how the colloid interacts with blood, and the consequences, e.g., impact on
erythrocytes, coagulation, and complement system. In this study, it was followed a pre-
viously described procedure appropriate to nanopharmaceutics [67,78,79]. Briefly, blood
samples, taken from three healthy adults (22, 26, and 43 years old), were poured into
flasks containing EDTA (before the haemolysis, and platelet activation experiments), or
NaH2(C3H5O (COO)3) (before the complement system activation, and plasma clotting
time assays). PBS was the negative control used in the experiments. The γ-Fe2O3 or the
(γ-Fe2O3/PLGA)/CS particles were kept in contact with the samples to evaluate their
interaction with blood. Validated UV spectrophotometric method was used in the assay
which was done in triplicate.
2.5. In-Vitro Quantification of CDDP Loading
Evaluation of the amount of antitumour agent loaded to the γ-Fe2O3/PLGA and
(γ-Fe2O3/PLGA)/CS particles was done in triplicate by UV spectrophotometric determina-
tions of the CDDP molecules remaining in the supernatant after NP centrifugation (60 min
and 11,000 rpm) (Centrifuge 5804, Eppendorf Ibérica S.L.U., Madrid, Spain). Considering
that quantity was not loaded and the total amount of chemotherapeutic was used, the
incorporation of CDDP to the NPs was determined. In these quantifications, contribu-
tions to the absorbance of sources other than variations in drug concentration, i.e., PVA,
CH3COOH, and Kolliphor® P-188, were taken into account by subtracting the absorbance
of the supernatant produced under the same conditions but without CDDP.
These UV absorption measurements were performed at the maximum absorbance
wavelength of this chemotherapeutic (301 nm) (Lambda™ 25 UV/Vis spectrophotometer,
PerkinElmer Inc., Waltham, MA, USA). Good linearity was observed at this wavelength
between absorbance and drug concentration data (r = 0.997), and the method was val-
idated and verified for precision, accuracy, and linearity. CDDP incorporation to the
magnetopolymeric NPs was calculated in terms of DL (%) (Equation (2)):
DL (%) =
Entrapped CDDP (mg)
CDDP− loaded NPs (mg) × 100 (2)
2.6. In-Vitro Quantification of CDDP Release
The CDDP release experiments were based on the dialysis bag method (n = 3), and
they were carried out using the (γ-Fe2O3/PLGA)/CS particles with the higher DLs (≈15%,
see Section 3). The release media were either C6H8O7-Na2HPO4 or C6H8O7-NaOH buffers
reproducing the pH of bloodstream (7.4 ± 0.1) or the acidic microenvironment in tumours
(pH 5.0 ± 0.1) [80], respectively. These in-vitro drug release media were kept either
at the normal human body-temperature (normothermia or euthermia, 37.0 ± 0.5 ◦C),
or at the representative temperature of magnetic hyperthermia-triggered drug release
experiments (45.0 ± 0.5 ◦C) [81–83]. The latter temperature is also the characteristic
maximum hyperthermia temperature of magnetic colloids commonly used as magnetic
hyperthermia agents for cancer treatment [83,84].
Before use, the dialysis bags (cut-off of 2000 Da, Spectrum® Spectra/Por® 6 dialysis
membrane tubing, New Brunswick, NJ, USA) were soaked in water at room temperature for
12 h. Then, 2 mL of the dispersion of CDDP-loaded (γ-Fe2O3/PLGA)/CS NPs (containing
2.5 mg/mL of chemotherapy agent) were poured into the bag with the two ends fixed by
clamps. The dialysis bags were placed in a glass beaker containing 0.1 L of release medium
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and stirred at 100 rpm. At prefixed time intervals, one mL of the medium was withdrawn
for UV spectrophotometric analysis of the CDDP content (at 301 nm). An equal volume
of the release media, kept also at 37.0 ± 0.5 or 45.0 ± 0.5 ◦C, was added after sampling to
maintain the sink conditions. The same analytical procedure used to determine the DL (%)
was used, and the in-vitro CDDP release was determined by using Equation (3):
CDDP released (%) =
Amount of CDDP released (mg)
Amount of CDDP loaded to the NPs (mg)
× 100 (3)
2.7. In-Vitro Cytotoxicity Assays
Blank (drug-unloaded) (γ-Fe2O3/PLGA)/CS NPs were tested in human colonic CCD-18
fibroblasts (Scientific Instrumentation Centre, University of Granada, Granada, Spain), and in
human colon carcinoma T-84 cells (American Type Culture Collection, Manassas, VA, USA).
According to the ISO-10993-5 standard [85], cell viability was tested (in triplicate) by the MTT
proliferation assay, determining mitochondrial dehydrogenase activity. Detailed methodology
has been described in the literature [67,79]. The cells were kept in contact with NP concentrations,
ranging from 0.05 to 100 µg/mL, for 48 and 72 h at 37.0± 0.5 ◦C in a humidified atmosphere of
5% CO2 in air (MCO-19AIC(UV) CO2 incubator, Sanyo, Osaka, Japan).
Cytotoxicity of the CDDP-loaded (core/shell)/shell particles against human lung
adenocarcinoma A-549 cells (American Type Culture Collection, Manassas, VA, USA) was
evaluated by the MTT assay in comparison with the free chemotherapy agent (n = 3). The
amount of these formulations in contact with the tumour cells ranged from 1 to 20 µg/mL
equivalent CDDP concentrations (NP concentrations from ≈ 6.5 to 130 µg/mL).
Cells without treatment were used as control to calculate the relative cell viability
(RCV, %) (Equation (4)).
RCV (%) =
Optical density of treated cells
Optical density of control (untreated) cells
× 100 (4)
The half maximal inhibitory concentration (IC50) values were estimated by a non-linear
regression analysis (GraphPad Prism 9.1.0, GraphPad Software Inc., La Jolla, CA, USA) [86,87].
2.8. Statistical Analysis
The IBM® SPSS® Statistics 26.0 software package (IBM Corporation, New York, NY, USA)
was used to that aim. Student’s t-test was done to compare results considering 95% confidence
interval. The experimental data were expressed as mean value ± SD, and the differences were
considered to be statistically significant at p < 0.05, or highly significant at p < 0.01.
3. Results and Discussion
On the basis of the experimental data collected in this Section, it is discussed how the
(γ-Fe2O3/PLGA)/CS (core/shell)/shell NPs are characterized by an appropriate size and
blood compatibility for intravenous administration, also probably by stealth properties; and,
more interestingly, by adequate magnetic-, pH-, and heat (hyperthermia)-sensitivities. All
these characteristics could make the nanocomposites an interesting nanocarrier for CDDP:
site-specific delivery of the antitumour agent could be considerably optimized, reaching
therapeutic levels inside the malignant cells. Of course, defining the real possibilities of
these CDDP-loaded nanostructures against lung cancer will only be possible if additional
in-vitro tests and, more significantly, experiments in tumour-bearing are done.
3.1. Characterization of the Nanoparticulate Systems
Mean diameter (and PdI) of γ-Fe2O3 nuclei, pure CS particles, and (γ-Fe2O3/PLGA)
NPs were: 10.2 ± 2.1, 364.1 ± 15.3, and 291.2 ± 1.8 nm, respectively. The methodology of
preparation of the (γ-Fe2O3/PLGA)/CS NPs reported adequate sizes (332.1 ± 82.1 nm),
and PPs (≈50%). These diameters are compatible with parenteral administration and could
favour NP accumulation at the cancer site (gaps of up to ≈ 600 nm between endothelial
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cells of the vasculature) [22,88]. Some studies have reported that particles up to 400 nm
may extravasate into the tumor tissue, taking advantage of the EPR effect [89–91]. For
instance, CDDP-loaded particles with sizes from 300 to 500 nm have been described to
reach the cancer site, inhibiting tumour growth after intravenous administration [60,92]. In
addition, early plasma clearance could be minimized thanks to the stealth property that
CS may provide to the (core/shell)/shell particles, and to their positive surface electrical
charge (ζ value: 23.6 ± 0.3 mV) [45,93]. These positive ζ values may further promote NP
internalization by the (negatively charged) cancer cell [49,94].
Regarding the short-term evaluation of the stability of these nanocomposites, data
in Table 1 illustrates the absence of relevant changes in the size (and PdI) and surface elec-
trical charge of the NPs. Therefore, it could be postulated that no particle aggregation will
occur after one month of storage at room temperature in water. The PDI values were ≤0.5
during the study, similarly to what has been previously described for PLGA-based NPs
surface functionalized with CS [95–97]. Such PDI data could be considered acceptable and
characteristic of relatively homogeneous NP dispersions [98,99].
Table 1. Particle diameter (nm), PdI, and ζ values (mV) of the (core/shell)/shell NPs as a function of
time (days). Data are expressed as means ± SDs of triplicate experiments.
Time Day 0 Day 1 Day 7 Day 14 Day 30
Size (nm) 332.1 ± 82.1 329.9 ± 168.3 333.8 ± 105.3 321.5 ± 97.8 334.9 ± 71.4
PdI 0.375 ± 0.006 0.422 ± 0.075 0.403 ± 0.036 0.289 ± 0.052 0.412 ± 0.077
ζ (mV) 23.6 ± 0.3 17.3 ± 0.7 23.3 ± 0.5 14.7 ± 1.8 26.3 ± 0.4
No significant effect on size was observed when the (γ-Fe2O3/PLGA)/CS NPs were
kept in contact with BSA (34, and 54 mg/mL concentrations in PBS), being the particle
diameter and PdI values ≈ 340 nm and ≈ 0.335, respectively. That negligible effect could
be attributed to the hydrophilic nature of the CS coating which could minimize protein
corona formation and particle aggregation [46,47].
HRTEM (Figure 2a), HAADF-STEM (Figure 2b), and ABF-STEM (Figure 2c) pho-
tographs demonstrated the satisfactory embedment of the γ-Fe2O3 nuclei into the poly-
meric nanostructure. Particle aggregation observed in Figure 2 could be the consequence of
the preparation of the samples by drying for the EM visualizations. This is a phenomenon
previously described in CS-based magnetic nanocomposites [100,101] that determined the
impossibility of identifying the shape of a single NP. On the other hand, the homogeneous
distribution of these iron oxide nanocores within the particle matrix is visible in the EDX
Fe element mapping of the (γ-Fe2O3/PLGA)/CS NPs (Figure 2d). Uniform coverage of
the γ-Fe2O3/PLGA particles by the CS shell can be postulated from the EDX N element
mapping of these (core/shell)/shell NPs (Figure 2e). Additionally, EDX analyses confirmed
the presence of the Fe, C, N, and O elements for the nanocomposites (Figure 3). The Fe
element arose from the γ-Fe2O3 cores and was only detected when the EDX spectrum
was taken from the centre of the (core/shell)/shell particles (Figure 3a). On the opposite,
the N element (from the CS shell) was identified in any EDX spectra taken of the NPs
(Figure 3a,b), thus confirming the homogeneous disposition of CS onto the core/shell
nanostructure. These observations established the formation of the (γ-Fe2O3/PLGA)/CS
(core/shell)/shell nanostructure. Finally, the existence of the Cu and Si elements in the
EDX analysis could arise from the use of copper-based grids [32] and the production of a
secondary fluorescence by the fluorescence detector [102].
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PLGA shell (at ≈1420 cm−1) [104]; (F) C–O bond stretching vibrations from a −OH group 
(at ≈1280 cm−1) [116]; (G) C–O bond stretching vibration from the carboxylic group in 
Figure 3. EDX spectra of: (a) the centre and (b) flank of the (core/shell)/shell NPs. Insets: HAADF-
STEM images of these nanoco osites (bar lengths: 100 m), and chemical structures of γ-Fe2O3,
PLGA and CS.
Pharmaceutics 2021, 13, 1232 10 of 22
Electrophoretic characterization of the colloids was then done to define qualitatively
the surface disposition of CS onto the (γ-Fe2O3/PLGA) (core/shell) particles. Concretely,
it was determined the surface electrical charge (ζ values) of the γ-Fe2O3/PLGA, CS,
and (γ-Fe2O3/PLGA)/CS NPs at predetermined ionic strengths (KNO3 molar concen-
trations) and pH ≈ 6 (the natural pH of the colloids). Similarities between the ζ values
of the CS and (γ-Fe2O3/PLGA)/CS particles, and how different they were from those
of the γ-Fe2O3/PLGA NPs are plotted in Figure 4a. The negative surface charge of the
γ-Fe2O3/PLGA particles may come from ionized weak acid groups, probably carboxylic-
end groups of PLGA [103,104]. On the opposite, the positive ζ values of pure CS and
(γ-Fe2O3/PLGA)/CS NPs could come from the residual amino groups existing in the
chemical structure of CS [42,105]. Finally, the decrease in the absolute values of ζ de-
scribed by the NPs at the larger ionic strengths should be the consequence of the classical
double-layer compression mechanism [106,107]. It can be observed in Figure 4a how the
ζ–ionic strength trend of the (γ-Fe2O3/PLGA)/CS NPs was dominated by the CS shell,
probably being that the consequence of the effective CS coating of the (γ-Fe2O3/PLGA)
particles. Finally, if the electrophoretic data in Figure 4a is considered, a mechanism could
be postulated to explain the generation of the (core/shell)/shell NPs: accumulation of CS
onto the γ-Fe2O3/PLGA surface may occur thanks to attractive interactions between the
negatively charged core/shell particles and the positively charged CS matrix [52,108].
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The infrared spectra of the (γ-Fe2O3/PLGA)/CS NPs is represented in Figure 4b. All
the characteristics bands of the polymers (CS and PLGA) were present in the spectrum
of these magnetopolymeric particles, hence demonstrating that the shell observed in Fig-
ure 2 corresponded well to the PLGA and CS shells onto the γ-Fe2O3 nuclei. Chemical
groups identified in the spectra were: (A) overlapped stretching vibrations from N–H
and O–H bonds (at ≈3400 cm−1) [109–111]; (B) C–H bond stretching vibration of −CH,
−CH2, and −CH3 groups (at ≈2850 cm−1) [109,110,112]; (C) C = O bond stretching vi-
bration of a carboxylic acid (at ≈1750 cm−1), probably from the PLGA shell [111,113,114];
(D) C = O bond stretching vibration of an amide group, presumably from the CS coat-
ing (≈1630 cm−1) [110,112,115]; (E) asymmetric CH2 bending vibration (at ≈1450 and
≈1380 cm−1) [110,112,113], and O–H bending vibration, probably from the carboxylic
group in the PLGA shell (at ≈1420 cm−1) [104]; (F) C–O bond stretching vibrations from
a −OH group (at ≈1280 cm−1) [116]; (G) C–O bond stretching vibration from the car-
boxylic group in PLGA (at ≈1160 cm−1) [104,116]; (H) C–O–C bond stretching vibration
from PLGA (at ≈1130 and ≈1080 cm−1) [97,104,112]; (I) medium band characteristic of
alkanes (at ≈890 cm−1) [117]; (J) CH rocking vibration characteristic of –CH long chains
(at ≈800 cm−1) [104,117]; and, (K) Fe–O bond vibration from pure iron oxide NPs
(at ≈560 cm−1) [104,118,119].
The X-ray diffraction patterns of γ-Fe2O3, and (γ-Fe2O3/PLGA)/CS NPs are plot-
ted in Figure 4c,d, respectively. They coincided with the American Society for Testing
and Materials (ASTM) pattern of γ-Fe2O3 (inset of Figure 4c) (ASTM No. 24-81). The
experimental data suggested that, after complete inclusion into the PLGA and CS shells,
the γ-Fe2O3 nuclei maintained a high crystallinity and mineralogical purity. These are
properties beneath an appropriate magnetic responsiveness and a superparamagnetic
behaviour [22]. 2θ values of the γ-Fe2O3 nanocores existing into the (γ-Fe2O3/PLGA)/CS
nanostructure were 29.89◦, 35.17◦, 43.43◦, 53.92◦, 56.87◦, and 63.12◦, and they may be
assigned to the (2 2 0), (3 1 1), (4 0 0), (4 2 2), (5 1 1), and (4 4 0) planes of these iron oxides,
respectively [120–122]. In addition, broad diffraction peaks were observed for CS and
PLGA particles at 2θ values ≈ 19.90◦ and ≈18.36◦, respectively (insets to Figure 4d). The
former peak would be indexed to the (1 1 0) plane that is characteristic of crystalline
chitin [123–125], while the diffraction peak observed for PLGA NPs could have come from
the amorphous phase of PLGA [126–128]. These broad peaks were integrated in the X-ray
diffractogram of the (γ-Fe2O3/PLGA)/CS NPs (2θ value≈ 18.57◦), probably a confirmation of
the efficiency of the preparation procedure in generating that (core/shell)/shell nanostructure.
The first magnetization curve of the (γ-Fe2O3/PLGA)/CS NPs, shown in Figure 5a,
characterized the appropriate magnetic responsiveness of this magnetic colloid. Initial
susceptibility and saturation magnetization values of the (core/shell)/shell particles were
(0.077 ± 0.003) × 10−3 m3/Kg and 5.03 ± 0.37 Am2/Kg, respectively. That adequate
magnetic responsive behaviour was further qualitatively confirmed by visual observation
of the colloid under exposure to a permanent magnet (Figure 5b): complete magnetic
attraction of the NPs toward the 400 mT magnet occurred in 120 s. However, in-vivo
experiments should be performed to define if this magnetic responsiveness could favour
the accumulation of the (γ-Fe2O3/PLGA)/CS particles at a targeted site.
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flat surface of the glass vial.
3.2. Cytotoxicity and Blood Compatibility
Data from the evaluation of the cytotoxicity of (γ-Fe2O3/PLGA)/CS NPs in normal
CCD-18 and tumour T-84 cells are represented in Figure 6, which illustrates how viability
of both cell lines was not altered by these (core/shell)/shell particles, even when the NP
concentration was increased from 0.05 to 100 µg/mL. According to ISO-10993-5 [85], the
RCV (%) values plotted in Figure 6 could be considered to be non-toxic. Additionally,
growth of cells kept in contact with non-cytotoxic blank (drug-unloaded) NPs has been de-
scribed to be not hindered, even at high concentrations [129–131]; as a result, proliferation
can continue under in-vitro conditions. On the other hand, experimental results from the
ex-vivo hemocompatibility assays of γ-Fe2O3 and (γ-Fe2O3/PLGA)/CS particles demon-
strated a negligible effect on haemolysis, platelet activation, complement system activation,
and plasma clotting time was observed (Table 2). Therefore, taking into account the results
from Figure 6 and Table 2, it could be postulated that the (γ-Fe2O3/PLGA)/CS NPs are
characterized by an adequate biocompatibility and safety for drug delivery purposes, being
suitable for parenteral administration.
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hydrophobic PLGA matrix [104]. It has been previously determined the very rapid pre-
cipitation of the polymer matrix, just upon contacting the H2O phase, when PLGA NPs 
are prepared by the nanoprecipitation solvent evaporation technique [103,133]. As a 
consequence, mechanical trapping of the drug inside that polymer network would be 
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Figure 6. In-vitro ytotoxicity (RCV, %) of the (γ-Fe2O3/PLGA)/CS NPs in CCD-18 cells at 48 h (blue
columns) and 72 h (green columns), and in T-84 cells at 48 h (dark blue columns) and 72 h (dark
green columns). These cell lines were kept in contact with NP concentrations, ranging from 0.05 to
100 µg/mL.
Table 2. Effect of the γ-Fe2O3, and (γ-Fe2O3/PLGA)/CS NPs on haemolysis (%), complement
activation (C3a release: C3a desArg, ng/mL), platelet activation (sP-selectin release, ng/mL), and
plasma recalcification time (T1/2 max, min). Data is indicated as means ± SDs (n = 3).
γ-Fe2O3 NPs
(γ-Fe2O3/PLGA)/CS
NPs Control (PBS Solution)
Haemolysis (%) 1.6 ± 0. 2.5 ± 0.4 0
C3a desArg (ng/mL) 296 ± 3 309 ± 8 290 ± 9
sP-selectin release
(ng/mL) 105 ± 6 117 ± 5 99 ± 6
T1/2 max (min) 14.1 ± 0.7 13.8 ± 1.2 12.2 ± 0.9
3.3. CDDP Loading
The conditions fixed to prepare the CDDP-loaded γ-Fe2O3/PLGA NPs tried to mini-
mize the escape of this hydrophilic drug [132] from mechanical trapping into the hydropho-
bic PLGA matrix [104]. It has been previously determined the very rapid precipitation
of the polymer matrix, just upon contacting the H2O phase, when PLGA NPs are pre-
pared by the nanoprecipitation solvent evaporation technique [103,133]. As a consequence,
mechanical trapping of the drug inside that polymer network would be facilitated [134].
Complementarily, stabilizing agents, e.g., poloxamers, PVA, may induce the opening of
the polymer chains to create a space within the PLGA matrix where the drug could be
incorporated [133,135]. Furthermore, CDDP incorporation to the PLGA matrix could be the
consequence of electrostatic attractions between drug molecules, positively charged when
the –NH group is protonated, and the negatively charged polymer (≈−10 mV at natural
pH 6). Electrostatic repulsions between the positively charged CDDP molecules and the
positively charged γ-Fe2O3 nuclei (≈+20 mV at natural pH 6) of these nanostructures may
prevent drug adsorption onto these iron oxides.
CDDP loading values to the γ-Fe2O3/PLGA, and (γ-Fe2O3/PLGA)/CS nanocom-
posites are compiled in Table 3. As expected, drug concentration positively influenced
CDDP absorption into the core/shell nanostructure, while no relevant modification of
the DL (%) values was observed when the γ-Fe2O3/PLGA particles were surface coated
with CS. In addition, CDDP incorporation to the (γ-Fe2O3/PLGA)/CS particles reported
greater DL values (≈15%) than those previously ascribed to non-magnetic PLGA/CS-
based particles (DL ≈ 9%) [49]. Finally, particle diameter and surface electrical charge of the
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(core/shell)/shell particles did not vary when loaded with the chemotherapy agent: ≈325 nm
and ≈+23 mV, respectively. The great similarity between the ζ values of the non-loaded
and the CDDP-loaded (γ-Fe2O3/PLGA)/CS particles may suggest an efficient absorption
of the CDDP molecules into the nanocomposites.
Table 3. Loading of CDDP (DL, %) to the γ-Fe2O3/PLGA, and (γ-Fe2O3/PLGA)/CS particles.
Nanoparticulate System [CDDP] (µg/mL) DL (%)
γ-Fe2O3/PLGA
3 0.021 ± 0.003
15 0.212 ± 0.079
30 0.995 ± 0.163
150 5.945 ± 0.364
300 16.057 ± 2.359
(γ-Fe2O3/PLGA)/CS 300 14.974 ± 3.025
3.4. CDDP Release
The pH-responsive CDDP release from the (γ-Fe2O3/PLGA)/CS NPs was evaluated
at 37.0 ± 0.5 ◦C by using release media reproducing either the pH ≈ 7.4 of bloodstream
or the acidic microenvironment in tumours (pH ≈ 5) (Figure 7). A biphasic drug release
profile was identified, which is characteristic of PLGA-based [58,67] and CS-based [42,60]
particles, and has been previously proposed for PLGA/CS (core/shell) nanostructures
loaded with Paclitaxel [49], and Itraconazole [136]. In detail, the process started with an
early-time burst drug release, taking place in ≈6 h (up to ≈21% at pH 7.4, and ≈39% at
pH 5.0). The remaining chemotherapeutic was then released slowly during around the
next 154 h at pH 7.4, and 66 h at pH 5.0. Such a biphasic CDDP release profile could
be attributed to drug diffusion through the PLGA/CS architecture in the initial stage
and to degradation/erosion of these polymer matrices during the final phase of drug
release [50,67,137], and may further suggest that the major proportion of CDDP molecules
was entrapped efficiently into the PLGA shell. Significantly, the pH-responsive CDDP
release behaviour was identified in Figure 7: ≈1.4-fold faster drug release at pH 5.0
compared to pH 7.4 (p < 0.05). In comparison with blood, the rapid drug release at the
acidic intratumoural pH may be the consequence of the higher solubility of CS at lower
pH values [42,43] and the accelerated degradation of PLGA by increased hydrolysis of the
backbone ester linkages in its chemical structure [36,37]. The existence of hydrophilic CS
shell onto the PLGA matrix could enhance the interaction of the NP with the acidic aqueous
medium, thus facilitating a faster degradation of PLGA by hydrolysis and, consequently,
the more rapid CDDP release compared to what occurred at the pH 7.4 of bloodstream [36].
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Figure 7. In-vitro release of CDDP (%) from the (γ-Fe2O3/PLGA)/CS (core/shell)/shell NPs as a
function of the incubation time (h) at 37.0 ± 0.5 ◦C, and pH 7.4 ± 0.1 (∆) or pH 5.0 ± 0.1 (N). Data is
presented as mean value ± SD (n = 3).
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The in-vitro CDDP release was considerably augmented when the NPs were kept at
the temperature commonly established in magnetic hyperthermia to trigger drug release
(45.0 ± 0.5 ◦C) [81–83,138]. At this temperature, CDDP release was a very rapid process
(Figure 8), decelerated when the (core/shell)/shell particles were kept at the physiological
pH of 7.4. Concretely, drug release was completed in ≈10 h at pH 7.4, and in ≈6 h at
pH 5.0. The fast CDDP release from the (γ-Fe2O3/PLGA)/CS NPs could be resulting from
both the enhanced permeability toward water and solutes displayed by the PLGA shell at
temperatures over the Tg [39] and the heat-mediated degradation of PLGA [40].
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Figure 8. In-vitro release of CDDP (%) from the (γ-Fe2O3/PLGA)/CS (core/shell)/shell NPs as a 
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Figure 8. In-vitro release of CDDP (%) from the (γ-Fe2O3/PLGA)/CS (core/shell)/shell NPs as a function
of the incubation time (h) at pH 7.4± 0.1 and 37.0± 0.5 ◦C (∆), pH 7.4± 0.1 and 45.0± 0.5 ◦C (#), and
pH 5.0 ± 0.1 and 45.0 ± 0.5 ◦C (•).
Taking into account the data in the Figures 7 and 8, it could be postulated that
the (γ-Fe2O3/PLGA)/CS particles can display a pH- and heat-responsive CDDP release
behaviour, generating a ≈4.7-fold faster drug release at pH 5.0 and 45 ◦C compared to
physiological conditions (pH 7.4 and 37 ◦C) (p < 0.05). This value was estimated at the
6 h time point: the moment when all the drug was released at pH 5.0 and 45 ◦C, while
only ≈21% of CDDP was released at pH 7.4 and 37 ◦C. Finally, and taking into account
the data plotted in the Figures 5 and 7, the CS-decorated particles could be considered
magnetic-, pH- and heat (hyperthermia)-responsive nanostructures probably facilitating
in vivo the selective accumulation of CDDP molecules into the tumour interstitium or even
intracellularly (inside the lysosomes of malignant cells after cellular uptake) [139–141].
3.5. Cytotoxicity against Human Lung Adenocarcinoma A-549 Cells
Figure 9 illustrates the dose-dependent inhibition of cancer cell growth displayed by
the CDDP formulations. At 3 to 20 µg/mL equivalent CDDP concentrations (NP concentra-
tions from ≈20 to 130 µg/mL)), it was observed a very significant enhancement of the anti-
tumour activity of the chemotherapeutic when being loaded to the (γ-Fe2O3/PLGA)/CS
particles (p < 0.01). They were the nanoformulations that could be considered with cytotoxic
potential, according to the ISO-10993-5 standard (RCV values < 70%) [85]. Furthermore,
the half maximal inhibitory concentration (IC50) of the CDDP-loaded (core/shell)/shell
NPs (4.57 ± 0.33 µg/mL) was ≈ 1.6-fold less than that of this platinum-based anticancer
drug (7.48 ± 0.37 µg/mL) (p < 0.05). This greater in-vitro cytotoxic activity agrees with
preceding research in which CDDP loading to nanoparticulate systems is postulated to
enable cellular uptake in malignant tissues [142,143].
Pharmaceutics 2021, 13, 1232 16 of 22
Pharmaceutics 2021, 13, x 17 of 24 
 
 
Taking into account the data in the Figures 7 and 8, it could be postulated that the 
(γ-Fe2O3/PLGA)/CS particles can display a pH- and heat-responsive CDDP release be-
haviour, generating a ≈4.7-fold faster drug release at pH 5.0 and 45 °C compared to 
physiological conditions (pH 7.4 and 37 °C) (p < 0.05). This value was estimated at the 6 h 
time point: the moment when all the drug was released at pH 5.0 and 45 °C, while only 
≈21% of CDDP was released at pH 7.4 and 37 °C. Finally, and taking into account the data 
plotted in the Figures 5 and 7, the CS-decorated particles could be considered magnetic-, 
pH- and heat (hyperthermia)-responsive nanostructures probably facilitating in vivo the 
selective accumulation of CDDP molecules into the tumour interstitium or even intra-
cellularly (inside the lysosomes of malignant cells after cellular uptake) [139–141]. 
3.5. Cytotoxicity against Human Lung Adenocarcinoma A-549 Cells 
Figure 9 illustrates the dose-dependent inhibition of cancer cell growth displayed by 
the CDDP formulations. At 3 to 20 μg/mL equivalent CDDP concentrations (NP concen-
trations from ≈20 to 130 μg/mL)), it was observed a very significant enhancement of the 
antitumour activity of the chemotherapeutic when being loaded to the 
(γ-Fe2O3/PLGA)/CS particles (p < 0.01). They were the nanoformulations that could be 
considered with cytotoxic potential, according to the ISO-10993-5 standard (RCV values < 
70%) [85]. Furthermore, the half maximal inhibitory concentration (IC50) of the 
CDDP-loaded (core/shell)/shell NPs (4.57 ± 0.33 μg/mL) was ≈ 1.6-fold less than that of 
this platinum-based anticancer drug (7.48 ± 0.37 μg/mL) (p < 0.05). This greater in-vitro 
cytotoxic activity agrees with preceding research in which CDDP loading to nanopartic-
ulate systems is postulated to enable cellular uptake in malignant tissues [142,143]. 
 
Figure 9. In-vitro cytotoxicity (RCV, %) of CDDP-loaded (γ-Fe2O3/PLGA)/CS NPs (black column) 
and free CDDP (light grey column) in human lung adenocarcinoma A-549 cells, after 72 h of ex-
posure to a wide range of NP concentrations (up to 20 μg/mL equivalent CDDP concentration). The 
statistical Student’s t-test, considering 95% confidence interval, was significant (* p < 0.05) or very 
significant (** p < 0.01, *** p < 0.001), compared with the free CDDP-treated group. 
Complementary in-vitro tests will help in providing clear evidence of the successful 
delivery of CDDP to tumour cells, and the real possibilities of these (core/shell)/shell NPs 
against lung cancer. For instance, the apoptosis assay involving annexin V/propidium 
iodide staining, the crystal violet staining experiment determining viability of cultured 
Figure 9. In-vitro cytotoxicity (RCV, %) of CDDP-loaded (γ-Fe2O3/PLGA)/CS NPs (black column)
and free CDDP (light grey column) in human lung adenocarcinoma A-549 cells, after 72 h of exposure
to a wide range of NP concentrations ( p to 20 µg/mL equivalent CDDP conc ntration). The
statistical Student’s t-test, considering 95% confidence interval, was significant (* p < 0.05) or very
significant (** p < 0.01, *** p < 0.001), compared with the free CDDP-treated group.
Complementary in-vitro tests will help in providing clear evidence of the successful
delivery of CDDP to tumour cells, and the real possibilities of these (core/shell)/shell NPs
against lung cancer. For instance, the apoptosis assay involving annexin V/propidium iodide
staining, the crystal violet staining experiment determining viability of cultured cells, and
colony forming and cell migration assays to characterize the proliferative competence of the
cancer cells on exposure to the CDDP-loaded NPs. Experiments in tumour-bearing mice will
be also needed to clearly define the anticancer effect of the CDDP-loaded nanocomposites.
4. Conclusions
A reproducible procedure has been developed to prepare (γ-Fe2O3/PLGA)/
CS (core/shell)/shell NPs loaded with the chemotherapeutic CDDP (≈330 nm in size,
PP ≈ 50%, DL ≈ 15%). That nanostructure was reasonably characterized by EM, EDX,
FTIR, and electrophoretic analyses. Short-term stability of the magnetic colloid was defined
at room temperature. The high crystallinity and mineralogical purity of the iron oxide
nuclei in the polymer matrices was proved by X-ray diffraction analysis, being that these
properties are possibly underneath the appropriate magnetism of the (γ-Fe2O3/PLGA)/CS
particles (demonstrated in vitro). Data from the cytotoxicity assays and ex-vivo hemocom-
patibility tests may suggest the in-vivo compatibility and safety of the (core/shell)/shell
NPs, being that they are suitable for parenteral administration (and drug delivery). Fur-
thermore, CDDP incorporation to this nanostructure generated a dual pH- and heat
(hyperthermia)-responsive drug release behaviour (≈4.7-fold faster CDDP release at pH 5.0
and 45 ◦C compared to pH 7.4 and 37 ◦C). To end, the CDDP-loaded (γ-Fe2O3/PLGA)/CS
particles demonstrated a better cytotoxicity than the free CDDP molecules against human
lung adenocarcinoma A-549 cells (IC50 ≈ 1.6-fold less than that of the chemotherapeutic)
in absence of an applied magnetic field. Altogether, these biocompatible and tri-stimuli
responsive (γ-Fe2O3/PLGA)/CS particles may become a contender in the lung cancer
arena. Additional in-vitro and in-vivo experiments will contribute to the perfect definition
of the therapeutic effectiveness of this nanostructure in cancer chemotherapy.
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